Page 1

oasmia Oasmia Pharmaceutical AB ( publ ) Interim report for the period January 1 , 2021 - June 30 , 2021 SIGNIFICANT EVENTS DURING THE SECOND QUARTER ● ● ● ● ● ● ● Oasmia Pharmaceutical AB ( publ ) - Interim report January 2021 - June 2021 ● ● In April , Oasmia appointed Dr Reinhard Koenig as Chief Scientific Officer . In April , Oasmia presented Cantrixil final Phase I data at the 2021 AACR Annual Meeting . ● In April , a Phase 1b trial of Oasmia's Docetaxel Micellar in advanced prostate cancer was granted ethical committee approval by Swissmedic . SECOND QUARTER : APRIL 1 , 2021 - JUNE 30 , 2021 Consolidated net sales amounted to TSEK 4,596 ( 254 ) Operating profit / loss was TSEK -56,165 ( -78,296 ) In May , Andrea Buscaglia was appointed as a new Board member by the Annual General Meeting . In June , following the ethical approval in April , the first Patient was enrolled in the Swiss Group for Clinical Cancer Research ( SAKK ) Investigator - Initiated Phase 1b trial of Docetaxel Micellar in advanced prostate cancer . In June , in addition to commercialization rights previously transferred for the rest of Europe , Oasmia also transfer the Nordic commercialization rights for Apealea® to Inceptua Group . In June , Cantrixil positive Phase I trial data were published in the open access oncology journal Cancers . THE PERIOD : JANUARY 1 , 2021 - JUNE 30 , 2021 Consolidated net sales amounted to TSEK 4,633 ( 201,474 ) Operating profit / loss was TSEK -97,007 ( 50,311 ) Net profit / loss after tax amounted to TSEK -98,889 ( 44,615 ) Earnings per share was SEK -0.22 ( 0.10 ) Net profit / loss after tax amounted to TSEK - 57,677 ( -80,090 ) Earnings per share was SEK -0.12 ( -0.18 ) Oasmia Pharmaceutical AB is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard - to - treat cancers . It has a growing pipeline of clinical - stage assets targeting late - stage cancers . Oasmia's most advanced program is Apealea® ( paclitaxel micellar ) , which is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics , Inc. Other development programs include Cantrixil , in clinical development for late - stage ovarian cancer , and docetaxel micellar , in development for advanced prostate cancer . Oasmia's proprietary drug delivery platform XR - 17 ™ is designed to improve drug solubility , efficacy and safety . Oasmia's shares are traded on Nasdaq Stockholm ( OASM ) . To find out more about Oasmia please visit www.oasmia.com . 1